不符合TNF抑制剂随机对照试验入选标准的银屑病关节炎患者治疗反应与药物生存率相似
基于ICEBIO登记数据的回顾性队列研究,纳入231例首次启用TNFi且有可用数据的银屑病关节炎患者,按各自TNFi对应的随机对照试验入选标准分为符合组与不符合组。两组随访6个月和18个月时疾病活动度相似,药物生存率亦相似;符合组基线肿胀关节数和DAS28-CRP更高。
要点
- 不符合RCT入选标准的PsA患者随访6个月和18个月疾病活动度与符合者相似
- 两组药物生存率相似
- 符合组基线SJC(5.5 vs 3.8)和DAS28-CRP(4.6 vs 4.2)更高
核心结论
- 不符合TNFi随机对照试验入选标准的银屑病关节炎患者,随访6个月和18个月达到与符合标准者相似的疾病活动度评分,且药物生存率相似。
研究设计与样本
- 回顾性队列研究,数据来自冰岛ICEBIO登记;2016年2月1日登记329例银屑病关节炎患者,其中231例有首次启用TNFi的数据并可按相应随机对照试验入选标准评估。
主要发现
- 两组基线人口学特征相似,但符合组肿胀关节数更高(5.5 vs 3.8),DAS28-CRP亦更高(4.6 vs 4.2)。
- 符合组在HAQ和肿胀关节数方面的疾病活动度变化更大,但两组随访时疾病活动度相似。
- 两组药物生存率相似。
关键数值与推荐
- 疾病活动度采用视觉模拟量表(疼痛、疲劳、整体评估(患者和医生))、肿胀关节数、压痛关节数、DAS28-CRP和HAQ采集。
- 治疗反应在6个月和18个月按美国风湿病学会反应标准、DAS28-CRP和28关节银屑病关节炎疾病活动度评分评估。
临床怎么用
- 对于因不符合随机对照试验入选标准而被视为「难治」或「不典型」的银屑病关节炎患者,TNFi仍可能获得与符合标准者相似的随访疾病活动度和药物生存率。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have fulfilled the inclusion criteria for randomised controlled trials (RCTs) for the TNF inhibitor (TNFi) chosen for their treatment (excl) have similar benefits and drug survival as those patients who would have (incl). METHODS: All patients with rheumatic disorders who are treated with biological disease-modifying antirheumatic drugs in Iceland are registered in ICEBIO. On 1 February 2016, 329 individuals with PsA were registered in ICEBIO, of whom 231 had data available for their first start of TNFi and could be evaluated according to the inclusion criteria of the respective RCTs. Disease activity was collected at baseline using Visual Analogue Scale (pain, fatigue and global (patient and physician) assessments), swollen joint count (SJC) and tender joint count (TJC), Disease Activity Score 28-joint count C reactive protein (DAS28-CRP) and Health Assessment Questionnaire (HAQ). Treatment response was measured at 6 and 18 months according to American College of Rheumatology response criteria, DAS28-CRP and Disease Activity Score in Psoriatic Arthritis for 28 joints. Drug survival rate was also analysed. RESULTS: The demographics of these two groups were similar at baseline, although the incl group had higher SJC (5.5 vs 3.8) and subsequently higher DAS28-CRP (4.6 vs 4.2). While a larger change in disease activity was observed in the incl group with respect to HAQ and SJC, both groups had similar disease activity at follow-up. Drug survival was similar in both groups. CONCLUSIONS: Patients with PsA who would not have fulfilled the inclusion criteria in RCTs reach similar disease activity scores at follow-up of 6 and 18 months and have similar drug survival as those patients who would have been included in RCTs.
引用
- Palsson O, Love TJ, Gunnarsdottir AI, et al. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. RMD Open. 2019. PMID: 31413869. doi:10.1136/rmdopen-2019-000984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。